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Abstract
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available
for severe combined immunodeficiency (SCID); although, there is a high incidence of severe infections and an
increased risk of graft-versus host-disease (GvHD) with HSCT. Early intervention is a crucial prognostic factor and a
HLA-haploidentical parental donor is often available. Haploidentical HSCT protocols utilizing extensively ex vivo T-cell
depleted grafts (CliniMACs system) have proven efficient in preventing GvHD, but cause a delay in early T-cell recovery
that increases the risk of viral infections. Here, we present a novel approach for treating SCID that combines selective
depletion of GvHD-inducing alpha/beta (α/β) T-cells from the haploidentical HSCT graft with a subsequent donor
lymphocyte infusion (DLI) enriched for CD45RO+ memory T-cells.
Results: Our patient was diagnosed with SCID (T-B + NK+ phenotype). At 9 months of age, he received a T cell
receptor(TCR)α/β-cell depleted graft from his haploidentical mother, following a reduced intensity conditioning
regimen with no additional GvHD prophylaxis. Engraftment was rapid with complete donor chimerism and no
signs of GvHD. However, at 12 weeks post HSCT, the patient was still T-cell lymphopenic with clinical symptoms
of multiple severe viral infections. Consequently, therapeutic DLIs were initiated for enhanced anti-viral immunity.
The patient was treated with CD45RA+ depleted haploidentical maternal donor lymphocytes enriched from unmobilized
whole blood, and a total T-cell dose of no more than 25 x103 CD3+ cells/kg with >99.9 % purity of CD3 + CD45RO+
memory T-cells was transferred. Following the DLI, a prompt increase in CD3 + CD4+ and CD3 + CD8+ counts was
observed with a subsequent clearance of viral infections. No acute or chronic GvHD was observed.
Conclusions: Automated depletion of CD45RA+ naïve T-cells from unmobilized whole blood is a simple and rapid
strategy to provide unmanipulated DLIs, with a potentially broad repertoire of pathogen specific memory T-cells. In the
haploidentical setting, CD45RA+ depleted DLIs can be safely administered at low T-cell doses for efficient enhancement
of viral immunity and limited risk of GvHD. We demonstrate the successful use of this approach following TCR-α/β-cell
depleted HSCT for the treatment of SCID.
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Background
Severe combined immunodeficiency (SCID) is a rare
disorder defined by a profound developmental or
functional defect of T lymphocytes. If unrecognized,
it can cause death during the first years of life, due
to the life-threatening increased susceptibility to infections
[1] therefore early detection and treatment of SCID, be-
fore infections become overwhelming, optimizes survival
[2–4]. Today, most forms of SCID are treated with
hematopoietic stem cell transplantation (HSCT) and if
HSCT is not successful and genetic treatment is not an
option, the alternatives are few [5].
For patients lacking a human leukocyte antigen (HLA)-
matched sibling or unrelated stem cell donor or when there
is an urgent need for a HSCT, an HLA-haploidentical par-
ental donor is often readily available [6]. Given the major
HLA donor-recipient disparities in the haploidentical set-
ting, measures are required to prevent the occurrence of
alloreactive responses, i.e. graft rejection or severe graft-
versus host-disease (GvHD). The extensive ex-vivo deple-
tion of donor T-cells (CliniMACS system) has proven effi-
cient in preventing GvHD [6, 7], but is inevitably coupled
to a delay in early T-cell recovery and, thus, to an increased
risk of viral infections [6–9]. Recent efforts to balance
the risk of GvHD against that of delayed immune
reconstitution include the selective depletion of GvHD-
inducing alpha/beta (α/β) T-cells while retaining poten-
tially beneficial gamma/delta (γ/δ) T-cells in the haploi-
dentical graft [10, 11].
Unselected donor lymphocyte infusions (DLIs), which
are frequently used as a “tool” to boost anti-viral immun-
ity post-transplant, harbor a significant risk of inducing
severe GvHD in the haploidentical setting [6, 7]. GvHD-
inducing cells reside mainly in the CD45RA+ naïve T-cell
population whereas viral-specific memory T-cells are pre-
dominantly CD45RA-negative [12]. Thus, the depletion of
CD45RA+ T cells from DLIs may provide a potentially
broad repertoire of donor-derived viral-immunity with a
limited risk of GvHD [13, 14].
Herein, we report on the successful treatment of SCID
by combining T cell receptor (TCR)-α/β-cell depleted




The male patient was born at full term, after a normal
pregnancy, as the third child of Afghanistani related par-
ents. Both parents and the siblings are healthy. He had his
first upper respiratory tract infection (URTI) at the age of
2 weeks and at the age of 1 month, he was admitted for
the first time to a pediatric ward for 2 weeks with cough-
ing, low grade fever and hoarseness. In the following
3 months, he was followed regularly due to coughing,
hoarseness and failure to thrive. At the age of 4 months,
he was infected with chicken-pox. Three weeks after the
onset of the infection, new blisters were still forming and
varicella keratitis developed. The unusually severe course
of the infection and the failure to thrive warranted investi-
gation for primary immunodeficiency disorder (PID), in
conformity with our protocol [15].
Investigations
Routine blood investigations during his first 4 months of
life showed normal leukocyte and neutrophil counts on
several occasions. Total lymphocytes were measured dur-
ing the first admission at 1 month of age, but the low
value of 0.6 (ref: 3–8.4 × 109/L) was attributed to an upper
respiratory tract infection (URTI) and was followed up
only at the beginning of the chicken-pox infection when
the level was 6.2x109/L. Other laboratory tests, including
electrolytes, ALT, AST, GT, pancreatic amylase, bilirubin,
organic acids, amino acids, and the thyroid hormone sta-
tus, were normal. At the time point of PID investigation,
he was anemic (hemoglobin: 81 g/L) with normal platelets
and a total lymphocyte count of 2.2x109/L. The immuno-
logical investigation revealed very low T-cell counts,
confirming a T-B +NK+ SCID phenotype. The cultures
taken at this point showed multiple infections: positive
Staphylococcus aureus blood culture, cytomegalovirus
(CMV), and varicella virus DNA positivity in blood, vari-
cella DNA in the cerebrospinal fluid, Pneumocystis jiroveci
and coronavirus NL63 on throat swabs, rotavirus in feces,
and high serum beta-d-glucan.
Genetic analysis
Genomic DNA was prepared from blood collected in
EDTA, fragmented to an average length of 300 bp, and
exome enriched using the SureSelect XT Human All
Exon v5 technology (Agilent). Sequencing was carried
out to an average coverage of 150-fold using PE 2x100
bp sequencing (Illumina HiSeq 2500). The bioinformatic
analysis was carried out using the Mutation Identifica-
tion Pipeline (MIP) [16]. Results were presented in an
interactive browser-based visualization tool (Scout), de-
veloped in-house (Science for Life Laboratory, Solna,
Sweden). The clinical interpretation of the results was
restricted to a predefined set of 233 genes known to be
involved in primary immunodeficiencies.
Sequence changes in exons and exon-intron boundaries
were analyzed. Only rare variants (allele frequency <0.01)
were considered. For recessive disease genes, at least two
variants were required. The analysis was not designed to
detect structural rearrangements or copy number alter-
ations. The exon sequencing, restricted to the predefined
set of 233 immunodeficiency genes, did not identify any
low-frequency variants that could account for the patient’s
clinical presentation. A homozygous missense variant
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(Val131Phe) in the CD3G gene, was identified, but it
received a low rank score due to its reported high fre-
quency of 0.21 in the 1000 Genomes database and was,
therefore, considered a natural variant. Thus, no known
genetic defect was identified.
Donor selection
Considering the low numbers of lymphocytes and the
life-threatening infections, the decision was made to per-
form a HSCT. The parents provided written informed
consent for this procedure. No HLA matched siblings
were available and the probability of finding a matched
unrelated donor was considered low given the patient´s
ethnical origin. Consequently, the choice was made to
select a HLA-haploidentical parental donor. The patient
and his parents were investigated according to our insti-
tutional protocol for haploidentical HSCT, including
high resolution allelic typing for HLA- A*, -B*, -C,*
DRB1*, DQB1*, BPB1* (PCR-sequence specific primers
[SSP], Olerup SSP AB), HLA-donor specific antibodies
(DSA) (LabScreen Singel Antigen, Luminex platform,
One Lambda, Thermo Fisher), ABO-blood grouping and
CMV-serology. The mother was selected as the donor
based on the outcome of the pre-transplant investigation,
and this selection was further supported by the reported
higher survival rate in haploidentical HSCT patients
grafted from the mother compared with recipients of
paternal grafts [17]. The HLA-typing confirmed patient
and donor haploidentity with a DRB1*, DQB1*, and
DPB1* allelic match in the host-versus-graft direction. No
DSA were detected in the patient´s serum. The patient
and the donor were matched for ABO-blood group and
were both CMV positive.
Transplant protocol
The patient was conditioned with a myeloablative
regimen, according to guidelines [18] regarding HSCT
for primary immunodeficiencies with a haploidentical
family donor in patients older than 3 months. How-
ever, due to his very poor health status, we decided
to use a reduced intensity regimen conditioning. This
consisted of i.v. anti-thymoglobuline (ATG Fresenius ®)
given from day -9 to -6 (first day 1 mg/kg bodyweight and
then 10 mg/kg bodyweight), fludarabine (40 mg/m2/day,
from day -7 to -4), thiotepa (5 mg/kg twice a day; day -3),
and melfalan (70 mg/m2 day -2 to -1). The sole form of
GvHD prevention was the immunomagnetic depletion of
TCR-α/β + cells from the graft. Prophylaxis against post-
transplant Epstein–Barr virus-associated lymphoprolif-
erative disease (EBV-PTLD) consisted of one dose of




Peripheral blood progenitor cells (PBPCs) of the haploi-
dentical maternal donor were mobilized by granulocyte-
colony-stimulating factor (G-CSF, 10 μg/kg/day) and
collected by leukapheresis (Cobe Spectra, Terumo BCT)
on day 4 of G-CSF administration. Collected PBPCs were
processed under clean room conditions with the Clini-
MACS system (Miltenyi Biotech), according to the manu-
facturer´s protocol. The cells were sequentially labelled
with TCR-α/β-Biotin reagent and CliniMACS anti-Biotin
reagent, and processed with the CliniMACS device using
the D3.1 program with the Depletion Tubing Set (DTS).
The graft cell contents were determined by flow cytometric
analysis (FACS, Canto II, Becton Dickinson [BD]), using
antibodies against CD45, CD34, CD14, CD19, CD56, CD3,
TCR-α/β and TCR-γ/δ with 7-AAD as a viability marker
(BD). According to our institutional protocol for haploi-
dentical HSCTs, the target cell dose of the TCR-α/β-cell
depleted graft was set to >10 × 106 CD34+ cells/kg (mini-
mum 5 × 106 CD34+/kg) and <25 × 103 TCR-α/β + cells/kg
(maximum 1× 105 TCR -α/β+ /kg).
Manufacturing of donor lymphocytes
A bag of unmobilized whole blood was drawn from the
donor. Utilizing a closed blood bag system, whole blood
was separated by density centrifugation to obtain a
leukocyte enriched cell fraction for further processing
with the CliniMACS system. According to the manufac-
turer´s protocol, cells were labelled with CD45RA re-
agent and processed under clean room conditions with
the CliniMACS device using the D3.1 program with the
DTS. The cell contents of the CD45RA-depleted target
fraction was assessed by FACS (Canto II, BD), using
antibodies against CD3, CD4, CD8, CD45RO, and
CD45RA with 7-AAD as a viability marker (BD).
Post-treatment evaluation
Engraftment following HSCT was monitored by daily
counts of leukocytes, neutrophils, and platelets. Immune
recovery was assessed post HSCT and after DLI by FACS
(Canto II, BD) of peripheral blood lymphocytes, using anti-
bodies against CD3, CD4, CD8, CD19, CD56, TCR-α/β,
TCR-γ/δ, CD45RA and CD45RO (BD). Donor myeloid
and T-cell chimerism was monitored by DNA genotyping
of short tandem repeat polymorphisms (PCR-STR, 3500
Dx Genetic Analyzer, Applied Biosystems). The patient
was evaluated for signs of acute and chronic GvHD.
Compliance with ethical guidelines
All procedures followed were in accordance with the
ethical standards of the Helsinki Declaration of 1975, as
revised in 2000. The Regional Ethical Review Board in
Lund, Sweden advised us that signed consent from the
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patient’s parents was sufficient for publication of this
case and the consent was obtained.
Results
Collection, depletion, and recovery
A single leukapheresis procedure provided 31 × 106
CD34+ cells/kg recipient weight for subsequent TCR-
α/β-cell depletion with the CliniMACS system. The
log10 TCR-α/β-cell depletion rate was -5.0, correspond-
ing to 0.005 % TCR-α/β + cells in the target fraction.
The recovery of CD34+ cells and TCR-γ/δ + cells was
99 %. Cell viability post-sorting was 98 %. The TCR-α/
β-depleted graft contained per kg of recipient weight
30.8 × 106 CD34+ cells, 0.11 × 105 TCR-α/β + cells,
29.7 × 106 TCR-γ/δ + cells, 237.7 × 106 CD19+ B-cells
and 162.2 × 106 CD56+ NK-cells and was transplanted
in total to the patient. The donor had antibodies
against CMV, VZV EBV and herpes simplex.
Engraftment and immunological reconstitution
Hematological recovery post HSCT was prompt with a
white blood cell count >1 × 109/L at day +10, neutro-
phils >0.5 × 109/L at day +12, and thrombocytes >50 ×
109/L at day +13. Complete myeloid and T-cell donor
chimerism was reached at day +19. As expected (16),
NK-cells co-infused with the graft expanded rapidly,
with normal peripheral counts from day + 14 (ref: 0.13–
0.72 × 109/L). However, despite the prompt three-linear
hematological recovery, the patient remained pro-
foundly T-cell lymphopenic (Fig. 1). ATG clearance
vary between individuals and the efficacy of ATG varies
between batches [19, 20]; therefore an explanation of
the lymphopenia could be that since we used ATG in a
relatively high dose, given timewise quite close to the
grafting, this affected the graft, hence could be consid-
ered as additional in vivo T-cell depletion. Due to the
persistent effect of rituximab, B-cell recovery was also
markedly delayed.
Donor lymphocyte infusions
A single unit of donor whole blood provided a surplus of
CD3+ cells (62.2 × 106/kg recipient weight) for subsequent
CD45RA+ depletion using the CliniMACS system.
The log10 CD3 +CD45RA+ cell depletion rate was -3.8,
corresponding to 0.0049 % residual CD3 +CD45RA+ cells
in the target fraction. The recovery of CD3 +CD45RO+
cells was 51 %. Cell viability post-sorting was 96 %. The tar-
get fraction contained 12.6 × 106 CD4 +CD45RO+ cells
and 1.3 × 106 CD8 +CD45RO+ cells per kg of recipient
weight, with an increased CD4+/CD8+ ratio compared
with the starting product (9.6 versus 2.1). Aliquots of
CD45RA+ depleted products containing 25 × 103 CD3+
cells/kg of recipient weight were prepared for fresh DLI
and cryopreservation. The patient received a fresh
CD45RA+ depleted DLI of 25 × 103 CD3+ cells/kg from
the original HSCT donor at day +84 post HSCT. At the
time of DLI (day +84 post HSCT), peripheral blood CD3 +
CD4+ and CD3 +CD8+ levels were <10 × 106 /L, but
reached 178 × 106 /L and 111 × 106/L, respectively, at
22 days following DLI. At 57 days after DLI, all T-
lymphocyte subset counts were normalized (Fig. 1),
corresponding to a continuously complete donor T-cell
chimerism. The circulating T-cells were predominantly
CD4 + CD45RA+ (935 × 106 /L) and CD8 + CD45RA+
(586 × 106 /L).
Post-transplant morbidity
The patient did not experience any acute GvHD after
HSCT or DLI. The early post-transplant period was
complicated at day +5 by acute mechanical ileus with
unknown etiology. This was resolved by mechanical ma-
nipulation during the exploratory laparotomy. The blood
tests showed continued VZV positivity and the numbers
of CMV copies were increasing. His condition deterio-
rated further and he suffered an Enterococcus faecium
septicemia at day +74, followed by severe diarrhea and
gastrointestinal tract bleeding, signs of probable colitis.
The stool analysis revealed CMV, in addition to rota-
virus. Two weeks after DLI, the test results showed that
the CMV was resistant to ganciclovir; therefore, the anti-
viral treatment was changed to foscarnet. Following DLI,
the time to clearance of VZV and rotavirus was 22 days.
The CMV levels decreased rapidly (Fig. 2) and the pa-
tient’s condition improved considerably. The stool analysis
for CMV was negative at 15 days following DLI and
cleared from peripheral blood at 73 days. Supplementation
with immunoglobulins was discontinued on day +99 post
HSCT. He was discharged approximately 6 months post
HSCT. No chronic GvHD was observed after the HSCT
or DLI. He developed blindness and one-sided micro-
phthalmia due to the varicella keratitis. At 21 months after
HSCT, the patient had a normal lymphocyte count with
normal lymphocyte subsets and neither new nor were
exacerbations of preexisting infections observed.
Discussion
Allogeneic HSCT is the only curative treatment available
for SCID, although it is associated with a high incidence of
severe infections and an increased risk of GvHD [2–4].
Early intervention is a crucial prognostic factor and the
prompt availability of a parental donor may favor the HLA-
haploidentical donor alternative. Haploidentical HSCT pro-
tocols utilizing extensively ex vivo T-cell depleted grafts
have proven efficient in preventing GvHD [6, 7]. The
remaining challenge of enhancing post-transplant immune-
reconstitution has been addressed by several investigators
by utilizing partially T-cell depleted grafts [10, 11, 21–23]
or adoptive transfer of donor immune cells [24–26]. Here,
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we present a novel approach for treating SCID, com-
bining TCR-α/β-cell depleted haploidentical HSCT
with CD45RA+ depleted DLI for a therapeutic anti-
viral boost.
Our patient received a TCR-α/β-cell depleted graft
from his haploidentical mother, following a reduced
intensity conditioning regimen with a short course of
ATG, a single dose of rituximab to prevent EBV-PTLD,
and no additional GvHD prophylaxis. Engraftment was
rapid with complete donor chimerism and no signs of
GvHD. However, at 12 weeks post HSCT, the patient
was still T-cell lymphopenic with clinical symptoms of
Fig. 1 Total lymphocyte count (TLC) and concentrations of different lymphocyte subsets (indicated by CD positivity) over time in relation to
hematopoietic stem cell transplantation (HSCT) and donor lymphocyte infusion (DLI). NK = Natural killer cells
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multiple severe viral infections. Consequently, the deci-
sion was made to initiate therapeutic DLIs for enhanced
anti-viral immunity.
In the haploidentical setting, unselected DLIs with a T-
cell add-back of only 25 × 103 CD3+ cells/kg may cause
severe GvHD [6, 7]. In contrast, enriched CD3 +CD45RO
+ memory T-cells may provide viral immunity with mark-
edly reduced alloreactivity [13, 14]. Notwithstanding,
cross-reactivity of memory viral-specific T-cells with mis-
matched HLA has been described and is, thus, a potential
source of GvHD in haploidentical HSCT [27]. Based on
these observations, the patient was treated with CD45RA+
depleted haploidentical donor lymphocytes, transferring a
total T-cell dose of no more than 25 × 103 CD3+ cells/kg
with >99.9 % purity of CD3+ CD45RO+ memory T-cells.
Following DLI, a prompt increase in CD3 + CD4+ and
CD3 + CD8+ counts was observed, with a concomitant
reduction in viral load and a subsequent clearance of viral
infections. No acute or chronic GvHD was observed. As
previously demonstrated [28], TCR-α/β cells could be
efficiently depleted (log -5.0) with the CliniMACS instru-
ment, preserving high numbers of CD34+ cells and
potentially beneficial TCR-gd + cells and NK-cells in the
graft. With the current approach of transferring a very low
dose of CD45RA+ depleted donor T-cells (25 × 103/kg
CD3+ cells), a sample of donor peripheral blood will pro-
vide sufficient numbers of lymphocytes.
To ensure that the manufacturing of DLIs was in com-
pliance with Good Manufacturing Process (GMP) condi-
tions, a closed blood bag system was used for the
collection and leukocyte enrichment of donor whole
blood and the CliniMACS instrument was used for sub-
sequent CD45RA+ depletion. Naïve T-cells (CD45RA+)
were efficiently depleted (log -3.8) providing sufficient
numbers of CD3 + CD45RO+ cells for the fresh DLI and
for cryopreservation. A benefit of the current protocol is
the time and cost effectiveness of using a whole blood
donation rather than a leukapheresis product as starting
material. Moreover, this approach is also less strenuous
for the donor.
A long-standing approach to control refractory viral in-
fections following HSCT is the generation of antigen-
specific T-cells against single pathogens such as CMV,
adenovirus, or EBV [29]. New strategies have been
Fig. 2 Viral load and antiviral treatment in relation to hematopoietic stem cell transplantation (HSCT) and donor lymphocyte infusion (DLI)
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developed for ex vivo selection of pathogen-specific donor
T-cells, using antigen induced stimulation and isolation by
cytokine secretion assay [24] or HLA-peptide streptamers
[25]. However, this approach is time consuming and tech-
nically much more demanding than the simple method of
cell depletion based on surface CD45RA+ antigen expres-
sion. Also, the generation of antigen stimulated T-cells for
clinical application is subjected to a more complex regula-
tory framework than that of CD45RA+ depleted, unma-
nipulated lymphocytes. Recently, the often limited
therapeutic effect of using antigen-specific T-cells has
been attributed to the limited in vivo persistence of trans-
ferred donor T-cells [29], suggesting that adoptive transfer
should include a variety of donor T-cell populations to
favor long-lasting clinical responses.
Very recently, three different groups [21, 22, 23] investi-
gated the use of CD45RA+ depletion as part of the haploi-
dentical or HLA-mismatched donor graft processing.
Using different conditioning regimens with different stem
cell sources and graft compositions, with or without ser-
otherapy, two of the groups [21, 23] reported limited or no
GvHD despite high numbers of transferred CD3 +
CD45RO+ T-cells (1-100 x 106/kg) while the third group
reported a 17.6 % incidence of grade III/IV acute GvHD.
Further studies are required to determine the optimal tim-
ing, T-cell dose, and source of CD45RA+ depleted donor
lymphocytes - as part of the graft or as prophylactic, pre-
emptive, or therapeutic DLIs.
Conclusion
Automated depletion of CD45RA+ naïve T-cells from
unmobilized whole blood donations is a simple and rapid
strategy to provide unmanipulated DLIs, with a potentially
broad repertoire of pathogen specific memory T-cells. In
the haploidentical setting, therapeutic CD45RA+ depleted
DLIs can be safely administered at low T-cell doses for
efficient enhancement of viral immunity and limited risk
of GvHD. We demonstrate the success of this approach
following TCR-α/β-cell depleted HSCT for the treatment
of SCID.
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